SCENESSE 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
II/0042 
Submission of an updated RMP in order to update the 
27/10/2022 
n/a 
Not applicable 
allergy and hypersensitivity risk from potential to 
identified, following reported cases of positive allergy 
test results, confirming the causal association 
between the allergies to afamelanotide. Consequently, 
the RMP has been revised to reclassify the important 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are 
issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD 
is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
potential risk Allergy and hypersensitivity to important 
identified risk. 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated by 
new additional data to be submitted by the MAH where 
significant assessment is required 
S/0041 
Annual re-assessment. 
22/04/2022 
n/a 
PSUSA/10314
Periodic Safety Update EU Single assessment - 
13/01/2022 
n/a 
PRAC Recommendation - maintenance 
/202106 
afamelanotide 
IAIN/0040 
A.1 - Administrative change - Change in the name 
04/01/2022 
PL 
and/or address of the MAH 
IB/0038 
B.II.b.3.z - Change in the manufacturing process of 
02/09/2021 
n/a 
the finished or intermediate product - Other variation 
II/0037 
B.I.a.1.c - Change in the manufacturer of AS or of a 
02/09/2021 
n/a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer uses a substantially different 
route of synthesis or manufacturing conditions 
S/0035 
6th annual re-assessment. 
20/05/2021 
n/a 
The CHMP, having reviewed the evidence of compliance with 
the specific obligations and the impact of the data submitted 
by the MAH on the benefit/risk profile of the medicinal 
product, concluded that marketing authorisation of 
SCENESSE should be maintained. 
Page 2/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0036 
A.7 - Administrative change - Deletion of 
10/03/2021 
n/a 
manufacturing sites 
PSUSA/10314
Periodic Safety Update EU Single assessment - 
14/01/2021 
n/a 
PRAC Recommendation - maintenance 
/202006 
afamelanotide 
II/0033 
Update of section 4.8 of the SmPC to revise the 
01/10/2020 
09/12/2020 
SmPC, 
As requested during Scenesse renewal procedure 
frequencies of adverse drug reactions (ADRs) based 
Labelling and 
(EMEA/H/C/002548/R/0026) and based on post-marketing 
on safety reports and to add new ADRS based on 
post-marketing spontaneous reports as requested 
during Scenesse Renewal procedure 
(EMEA/H/C/002548/R/0026); the Package Leaflet is 
updated accordingly. The revised RMP version 9.0 (in 
line with rev 2 of the template) is acceptable. In 
addition, the MAH took the opportunity to introduce 
minor editorial changes in section 2 of the SmPC and 
Annex IIIA. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
PL 
spontaneous reports, the MAH updated section 4.8 of the 
SmPC to add new ADRs, to revise frequency of known ADRs 
and to update some preferred terms in line with MedDRA. For 
further information, please refer to the SmPC. Additionally, 
‘administration site reactions’ was removed from the list of 
safety concerns of the RMP. 
S/0032 
5th annual re-assessment 
30/04/2020 
n/a 
The CHMP, having reviewed the evidence of compliance with 
the specific obligations and the impact of the data submitted 
by the MAH on the benefit/risk profile of the medicinal 
product, concluded that the marketing authorisation under 
exceptional circumstances of Scenesse should be 
maintained. 
PSUSA/10314
Periodic Safety Update EU Single assessment - 
16/01/2020 
n/a 
PRAC Recommendation - maintenance 
/201906 
afamelanotide 
Page 3/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0031/G 
This was an application for a group of variations. 
16/12/2019 
n/a 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
IAIN/0030/G 
This was an application for a group of variations. 
12/12/2019 
09/12/2020 
Annex II and PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - Not 
including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - Not 
including batch control/testing 
Page 4/9 
 
 
 
 
 
 
 
 
 
 
 
R/0026 
Renewal of the marketing authorisation. 
19/09/2019 
19/11/2019 
SmPC, Annex II 
Based on the review of data on quality, safety and efficacy, 
and PL 
the CHMP considered that the benefit-risk balance of 
SCENESSE in the approved indication remains favourable 
and therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
IAIN/0028 
B.II.b.2.c.1 - Change to importer, batch release 
19/07/2019 
19/11/2019 
SmPC, Annex 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - Not 
including batch control/testing 
II, Labelling 
and PL 
PSUSA/10314
Periodic Safety Update EU Single assessment - 
11/07/2019 
n/a 
PRAC Recommendation - maintenance 
/201812 
afamelanotide 
S/0023 
4th annual re-assessment 
26/04/2019 
n/a 
The CHMP, having reviewed the evidence of compliance with 
the specific obligations and the impact of the data submitted 
by the MAH on the benefit/risk profile of the medicinal 
product, concluded that the marketing authorisation under 
exceptional circumstances of Scenesse should be 
maintained. 
IAIN/0027/G 
This was an application for a group of variations. 
12/04/2019 
19/11/2019 
SmPC, Annex 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
II, Labelling 
and PL 
Page 5/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - Not 
including batch control/testing 
T/0024 
Transfer of Marketing Authorisation 
08/02/2019 
20/03/2019 
SmPC, 
Labelling and 
PL 
IB/0022 
B.II.b.1.f - Replacement or addition of a 
25/01/2019 
n/a 
manufacturing site for part or all of the manufacturing 
process of the FP - Site where any manufacturing 
operation(s) take place, except batch release, batch 
control, and secondary packaging, for sterile medicinal 
products (including those that are aseptically 
manufactured) excluding biological/ immunological 
medicinal products 
PSUSA/10314
Periodic Safety Update EU Single assessment - 
17/01/2019 
n/a 
PRAC Recommendation - maintenance 
/201806 
afamelanotide 
PSUSA/10314
Periodic Safety Update EU Single assessment - 
12/07/2018 
n/a 
PRAC Recommendation - maintenance 
/201712 
afamelanotide 
S/0019 
3rd annual re-assessment. 
26/04/2018 
n/a 
The CHMP, having reviewed the evidence of compliance with 
the specific obligations and the impact of the data submitted 
by the MAH on the benefit/risk profile of the medicinal 
product, concluded that marketing authorisation of 
Page 6/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCENESSE should be maintained. 
II/0018 
C.I.11.b - Introduction of, or change(s) to, the 
08/03/2018 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated by 
new additional data to be submitted by the MAH where 
significant assessment is required 
II/0017 
B.II.c.1.d - Change in the specification parameters 
25/01/2018 
n/a 
and/or limits of an excipient - Change outside the 
approved specifications limits range 
PSUSA/10314
Periodic Safety Update EU Single assessment - 
11/01/2018 
n/a 
PRAC Recommendation - maintenance 
/201706 
afamelanotide 
IA/0015 
A.4 - Administrative change - Change in the name 
10/08/2017 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
PSUSA/10314
Periodic Safety Update EU Single assessment - 
06/07/2017 
n/a 
PRAC Recommendation - maintenance 
/201612 
afamelanotide 
IB/0013 
B.II.f.1.e - Stability of FP - Change to an approved 
10/05/2017 
n/a 
stability protocol 
S/0011 
Annual re-assessment. 
21/04/2017 
n/a 
PSUSA/10314
Periodic Safety Update EU Single assessment - 
12/01/2017 
n/a 
PRAC Recommendation - maintenance 
/201606 
afamelanotide 
Page 7/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10314
Periodic Safety Update EU Single assessment - 
07/07/2016 
n/a 
PRAC Recommendation - maintenance 
/201512 
afamelanotide 
S/0007 
1st  Annual Re-assessment 
26/05/2016 
n/a 
The CHMP, having reviewed the evidence of compliance with 
the specific obligations and the impact of the data submitted 
by the MAH on the benefit/risk profile of the medicinal 
product, concluded that Marketing Authorisation of Scenesse 
should be maintained. 
IA/0008 
B.II.d.1.d - Change in the specification parameters 
03/03/2016 
n/a 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
PSUSA/10314
Periodic Safety Update EU Single assessment - 
14/01/2016 
n/a 
PRAC Recommendation - maintenance 
/201506 
afamelanotide 
IB/0006 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf life 
01/12/2015 
12/08/2016 
SmPC 
of the finished product - As packaged for sale 
(supported by real time data) 
IA/0005 
B.II.b.2.a - Change to importer, batch release 
04/09/2015 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IAIN/0003/G 
This was an application for a group of variations. 
21/08/2015 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
Page 8/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
IAIN/0002/G 
This was an application for a group of variations. 
27/07/2015 
12/08/2016 
SmPC, Annex 
II, Labelling 
and PL 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
IB/0001 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
16/06/2015 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
Page 9/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
